MCRB - Seres Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

MCRB

SERES THERAPEUTICS, INC.

NASDAQ

$5.11

▲ UP 3.23% (0.16)

KEY STATISTICS

Market Cap$49.48 M

52w High$29.98

52w Low$4.32

Dividend Yield—

Frequency—

P/E-2.00

Volume32.49K

Shares Out.9.68M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Richard N. Kender

COMPENSATION 2026

Salary$494,400

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$6,039

Total$1,113,396

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 26, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$12.00

Target Low$12.00

Target Median$12.00

Target Consensus$12.00

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$6.35M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-04-22	Reverse	1:20

PRICE

$5.11 ▲ UP 3.23% (+$0.16)

OVERLAYS

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com ↗

Seres Therapeutics, a Cambridge-based microbiome platform company, develops bacterial therapies like SER-109 for CDI and others in clinical trials to treat various diseases, including infections, ulcerative colitis, and cancer.

INDUSTRY

Biotechnology

A PRODUCT SERES THERAPEUTICS, INC. IS KNOWN FOR

SER-155

Seres Therapeutics' investigational oral live biotherapeutic aims to prevent bloodstream infections in vulnerable patients, especially post-stem cell transplantation, and is their primary focus after selling VOWST, with promising clinical trial re...